Objective:

To explore the evolving landscape of advanced breast cancer diagnostics, particularly focusing on ESR1 mutation testing and the implications for precision diagnostics.

Key Findings:

• ESR1 mutations drive resistance in estrogen receptor-positive, HER2-negative breast cancer.
• New SERD therapies are being developed, with liquid biopsy tests as the approved companion diagnostics.
• Digital PCR (ddPCR) offers cost-effective, sensitive testing compared to next-generation sequencing (NGS).
• IHC is not suitable for resistance monitoring due to its inability to detect ESR1 mutations, which are critical for treatment decisions.

Interpretation:

The diagnostics industry is shifting towards more accessible and cost-effective testing solutions, particularly through the use of ddPCR technology, to better meet the needs of patients with advanced breast cancer.

Limitations:

• Centralized testing models may limit patient accessibility due to high costs and reimbursement challenges.
• High costs of NGS and reimbursement challenges hinder widespread adoption, particularly affecting patient access to necessary tests.

Conclusion:

The collaboration between Biodesix and Bio-Rad aims to enhance the availability of sensitive and quantifiable tests for ESR1 mutations, addressing current diagnostic challenges in breast cancer treatment through innovative solutions.